Impact of Previous HPV Infection and CD4 T-Cell Levels on Immune Responses to a Three-Dose Nonavalent HPV Vaccine in Individuals with HIV Undergoing ART - Summary - MDSpire

Impact of Previous HPV Infection and CD4 T-Cell Levels on Immune Responses to a Three-Dose Nonavalent HPV Vaccine in Individuals with HIV Undergoing ART

  • By

  • Eeva Tortellini

  • Mariasilvia Guardiani

  • Anna Carraro

  • Lorenzo Ansaldo

  • Sara Corazza

  • Sara Giovanna De Maria

  • Silvia Garattini

  • Mirko Barresi

  • Valeria Belvisi

  • Maria Antonella Zingaropoli

  • Federica Dominelli

  • Carmen Falvino

  • Fabio Mengoni

  • Alessandro Tavelli

  • Cristina Giambi

  • Claudio Maria Mastroianni

  • Cosmo Del Borgo

  • Raffaella Marocco

  • Miriam Lichtner

  • December 24, 2025

  • 0 min

Share

Objective:

To characterize the T-cell response to the Gardasil 9® HPV vaccine in people with HIV (PWH), focusing on the effects of prior HPV infection and CD4 T-cell count, and to assess the implications for vaccination strategies.

Key Findings:
  • PWH have a higher incidence of HPV infection and related cancers compared to HIV-uninfected individuals, necessitating targeted vaccination efforts.
  • The immune response to the Gardasil 9® vaccine in PWH is comparable to that in the general population, indicating effective immunogenicity.
  • Higher CD4 T-cell counts correlate with better T-cell responses to the vaccine, suggesting the need for monitoring CD4 levels in vaccination strategies.
  • Prior HPV infection status influences T-cell responses post-vaccination, highlighting the importance of individual patient history.
Interpretation:

The study suggests that both prior HPV infection and CD4 T-cell levels significantly affect the immune response to the HPV vaccine in PWH, emphasizing the need for tailored vaccination strategies to enhance efficacy.

Limitations:
  • The study was conducted at a single center, which may limit generalizability and applicability to broader populations.
  • Exclusion of individuals with other chronic viral infections may affect the findings, potentially underrepresenting the complexity of immune responses in diverse patient populations.
Conclusion:

The findings underscore the importance of considering prior HPV infection and CD4 T-cell counts when evaluating vaccine responses in PWH, suggesting potential avenues for improving vaccination strategies tailored to individual patient profiles.

Original Source(s)

Impact of Previous HPV Infection and CD4 T-Cell Levels on Immune Responses to a Three-Dose Nonavalent HPV Vaccine in Individuals with HIV Undergoing ART

  • by Eeva Tortellini, Mariasilvia Guardiani, Anna Carraro, Lorenzo Ansaldo, Sara Corazza, Sara Giovanna De Maria, Silvia Garattini, Mirko Barresi, Valeria Belvisi, Maria Antonella Zingaropoli, Federica Dominelli, Carmen Falvino, Fabio Mengoni, Alessandro Tavelli, Cristina Giambi, Claudio Maria Mastroianni, Cosmo Del Borgo, Raffaella Marocco, Miriam Lichtner

  • December 24, 2025

Related Content

The U.S. Government and Gavi, the Vaccine Alliance

A CDC page on mpox caught in political crosshairs

Novel BPI3Vc-vectored chimeric BVDV antigens elicit broadly neutralizing antibodies in cattle